Mainz Biomed making advancements in cancer detection technology, with new studies and partnerships.

From GlobeNewswire: 2025-04-28 08:01:00

Mainz Biomed N.V. provided an update on its first quarter accomplishments in 2025, including enrolling the first patient in its feasibility study for a next-generation colorectal cancer test. The company also signed agreements for access to novel mRNA biomarkers for pancreatic cancer detection and launched an enhanced CRC screening test in Germany. Additionally, Mainz Biomed entered a partnership to introduce a DNA-based CRC screening test in Switzerland for the first time. The company is on track for FDA premarket approval and regained compliance with Nasdaq listing requirements.

Mainz Biomed, a molecular genetics diagnostic company, is making significant strides in cancer detection, with new studies and partnerships paving the way for FDA approval. The company’s innovative approach to screening tests for colorectal and pancreatic cancer is showing promising results, with high sensitivity and specificity rates. By expanding its presence in Europe and meeting regulatory requirements, Mainz Biomed is positioning itself as a leader in early cancer detection technology. Investors and stakeholders can find more information on the company’s official website and social media channels.



Read more at GlobeNewswire: Mainz Biomed Provides First Quarter 2025 Corporate Update